Literature DB >> 25395817

Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Diana Khaybullina, Ami Patel, Tina Zerilli.   

Abstract

Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Entities:  

Year:  2014        PMID： 25395817      PMCID： PMC4218670     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  19 in total

1.  Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

Authors:  H A Ghofrani; M M Hoeper; M Halank; F J Meyer; G Staehler; J Behr; R Ewert; G Weimann; F Grimminger
Journal:  Eur Respir J       Date:  2010-06-07       Impact factor: 16.671

2.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

Review 3.  Updated treatment algorithm of pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Paul A Corris; Adaani Frost; Reda E Girgis; John Granton; Zhi Cheng Jing; Walter Klepetko; Michael D McGoon; Vallerie V McLaughlin; Ioana R Preston; Lewis J Rubin; Julio Sandoval; Werner Seeger; Anne Keogh
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

4.  Riociguat for pulmonary hypertension--a glass half full.

Authors:  Stephen L Archer
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.

Authors:  Reiner Frey; Wolfgang Mück; Sigrun Unger; Ulrike Artmeier-Brandt; Gerrit Weimann; Georg Wensing
Journal:  J Clin Pharmacol       Date:  2008-06-02       Impact factor: 3.126

Review 6.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

7.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

8.  Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.

Authors:  Marius M Hoeper; Michael Halank; Heinrike Wilkens; Andreas Günther; Gerrit Weimann; Irmingard Gebert; Hanno H Leuchte; Jürgen Behr
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

Review 9.  Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.

Authors:  H A Ghofrani; F Grimminger
Journal:  Eur Respir Rev       Date:  2009-03

10.  Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

Authors:  Diana Bonderman; Stefano Ghio; Stephan B Felix; Hossein-Ardeschir Ghofrani; Evangelos Michelakis; Veselin Mitrovic; Ronald J Oudiz; Francis Boateng; Andrea-Viviana Scalise; Lothar Roessig; Marc J Semigran
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690
View more
  16 in total

1.  Elucidation of cGMP-dependent induction of mitochondrial biogenesis through PKG and p38 MAPK in the kidney.

Authors:  Pallavi Bhargava; Jaroslav Janda; Rick G Schnellmann
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-16

2.  Mapping of the sGC Stimulator BAY 41-2272 Binding Site on H-NOX Domain and Its Regulation by the Redox State of the Heme.

Authors:  Garyfallia I Makrynitsa; Aikaterini I Argyriou; Aikaterini A Zompra; Konstantinos Salagiannis; Vassiliki Vazoura; Andreas Papapetropoulos; Stavros Topouzis; Georgios A Spyroulias
Journal:  Front Cell Dev Biol       Date:  2022-06-17

Review 3.  Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension.

Authors:  Adrija Hajra; Israel Safiriyu; Prasanth Balasubramanian; Rahul Gupta; Selia Chowdhury; Abhishek J Prasad; Akshay Kumar; Deepak Kumar; Baseer Khan; Roberta S F Bilberry; Ankit Sarkar; Paras Malik; Wilbert S Aronow
Journal:  Curr Probl Cardiol       Date:  2022-04-29       Impact factor: 16.464

Review 4.  Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat.

Authors:  Zachary R Smith; Charles T Makowski; Rana L Awdish
Journal:  Ther Clin Risk Manag       Date:  2016-06-10       Impact factor: 2.423

Review 5.  Kidney dysfunction in patients with pulmonary arterial hypertension.

Authors:  N P Nickel; J M O'Leary; E L Brittain; J P Fessel; R T Zamanian; J D West; E D Austin
Journal:  Pulm Circ       Date:  2017-03-13       Impact factor: 3.017

6.  Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Authors:  Y Kapelyukh; C J Henderson; N Scheer; A Rode; C R Wolf
Journal:  Drug Metab Dispos       Date:  2019-05-30       Impact factor: 3.922

7.  Drug repositioning in pulmonary arterial hypertension: challenges and opportunities.

Authors:  Daniel Grinnan; Cory Trankle; Adam Andruska; Bruce Bloom; Edda Spiekerkoetter
Journal:  Pulm Circ       Date:  2019 Jan-Mar       Impact factor: 3.017

8.  Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains.

Authors:  Rana Rehan Khalid; Muhammad Tahir Ul Qamar; Arooma Maryam; Ayesha Ashique; Farooq Anwar; Mohammed H Geesi; Abdul Rauf Siddiqi
Journal:  Molecules       Date:  2018-08-25       Impact factor: 4.411

9.  Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice.

Authors:  Danica Michaličková; Pavel Jansa; Miroslava Bursová; Tomáš Hložek; Radomír Čabala; Jan Miroslav Hartinger; David Ambrož; Michael Aschermann; Jaroslav Lindner; Aleš Linhart; Ondřej Slanař; Elke H J Krekels
Journal:  Pulm Circ       Date:  2020-02-10       Impact factor: 3.017

Review 10.  Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis.

Authors:  Saja Almaaitah; Kristin B Highland; Adriano R Tonelli
Journal:  Integr Blood Press Control       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.